Interferon beta-1a vs. glatiramer acetate: changes of innate
immunity in a group of women with multiple sclerosis

J 2023

Interferon beta-1a vs. glatiramer acetate: changes of innate immunity in a group of women with multiple sclerosis

PETERKA, Marek, Martin VALIS, Ondrej SOUCEK, Jan KREJSEK, Lukas SOBISEK et. al.

Základní údaje

Originální název

Interferon beta-1a vs. glatiramer acetate: changes of innate immunity in a group of women with multiple sclerosis

Autoři

PETERKA, Marek (203 Česká republika), Martin VALIS (203 Česká republika), Ondrej SOUCEK (203 Česká republika), Jan KREJSEK (203 Česká republika), Lukas SOBISEK (203 Česká republika), Ilona SEJKOROVA (203 Česká republika), Blanka KLIMOVA (203 Česká republika), Pavel ŠTOURAČ (203 Česká republika, domácí), Zbysek PAVELEK (203 Česká republika) a Michal NOVOTNY (203 Česká republika)

Vydání

EUROPEAN NEUROLOGY, BASEL, KARGER, 2023, 0014-3022

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30210 Clinical neurology

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.400 v roce 2022

Kód RIV

RIV/00216224:14110/23:00133490

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1159/000532022

UT WoS

001036985900001

Klíčová slova anglicky

Multiple Sclerosis; Interferon Beta-1a; Glatiramer Acetate

Štítky

14110221, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 5. 4. 2024 09:29, Mgr. Tereza Miškechová

Anotace

V originále

Introduction: Multiple sclerosis is a chronic inflammatory autoimmune demyelinating disease that secondarily leads to the axonal loss and associated brain atrophy. Disease-modifying drugs (DMDs) have previously been studied for their ability to affect specific immunity. This study investigates the effect of interferon beta-1a (INF) and glatiramer acetate (GA) administration on changes in innate immunity cell populations. Methods: Sixty Caucasian female patients with relapsing-remitting multiple sclerosis undergo blood sample testing for 15 blood parameters at baseline, 1M, 3M and 6M after treatment by GA or IFN (started as their first line DMD). Results: A statistically significant difference in the change after 6 months was found in the parameter monocytes (relative count) in the group of patients treated with IFN. The median increase was 27.8%. Changes in many of the other 15 parameters studied were 10-20%. Conclusion: Innate immunity has long been neglected in MS immunopathology. The findings of this study show that innate immunity cells, especially monocytes may contribute significantly to MS immunopathology.

Citovat

PETERKA, Marek, Martin VALIS, Ondrej SOUCEK, Jan KREJSEK, Lukas SOBISEK, Ilona SEJKOROVA, Blanka KLIMOVA, Pavel ŠTOURAČ, Zbysek PAVELEK a Michal NOVOTNY. Interferon beta-1a vs. glatiramer acetate: changes of innate immunity in a group of women with multiple sclerosis. EUROPEAN NEUROLOGY. BASEL: KARGER, 2023, roč. 86, č. 5, s. 334-340, 14 s. ISSN 0014-3022. Dostupné z: https://dx.doi.org/10.1159/000532022.

@article{2371617,
   author = {Peterka, Marek and Valis, Martin and Soucek, Ondrej and Krejsek, Jan and Sobisek, Lukas and Sejkorova, Ilona and Klimova, Blanka and Štourač, Pavel and Pavelek, Zbysek and Novotny, Michal},
   article_location = {BASEL},
   article_number = {5},
   doi = {http://dx.doi.org/10.1159/000532022},
   keywords = {Multiple Sclerosis; Interferon Beta-1a; Glatiramer Acetate},
   language = {eng},
   issn = {0014-3022},
   journal = {EUROPEAN NEUROLOGY},
   title = {Interferon beta-1a vs. glatiramer acetate: changes of innate immunity in a group of women with multiple sclerosis},
   url = {https://karger.com/ene/article/86/5/334/860198/Interferon-Beta-1a-versus-Glatiramer-Acetate},
   volume = {86},
   year = {2023}
}

TY  - JOUR
ID  - 2371617
AU  - Peterka, Marek - Valis, Martin - Soucek, Ondrej - Krejsek, Jan - Sobisek, Lukas - Sejkorova, Ilona - Klimova, Blanka - Štourač, Pavel - Pavelek, Zbysek - Novotny, Michal
PY  - 2023
TI  - Interferon beta-1a vs. glatiramer acetate: changes of innate immunity in a group of women with multiple sclerosis
JF  - EUROPEAN NEUROLOGY
VL  - 86
IS  - 5
SP  - 334-340
EP  - 334-340
PB  - KARGER
SN  - 00143022
KW  - Multiple Sclerosis
KW  - Interferon Beta-1a
KW  - Glatiramer Acetate
UR  - https://karger.com/ene/article/86/5/334/860198/Interferon-Beta-1a-versus-Glatiramer-Acetate
N2  - Introduction: Multiple sclerosis is a chronic inflammatory autoimmune demyelinating disease that secondarily leads to the axonal loss and associated brain atrophy. Disease-modifying drugs (DMDs) have previously been studied for their ability to affect specific immunity. This study investigates the effect of interferon beta-1a (INF) and glatiramer acetate (GA) administration on changes in innate immunity cell populations. Methods: Sixty Caucasian female patients with relapsing-remitting multiple sclerosis undergo blood sample testing for 15 blood parameters at baseline, 1M, 3M and 6M after treatment by GA or IFN (started as their first line DMD). Results: A statistically significant difference in the change after 6 months was found in the parameter monocytes (relative count) in the group of patients treated with IFN. The median increase was 27.8%. Changes in many of the other 15 parameters studied were 10-20%. Conclusion: Innate immunity has long been neglected in MS immunopathology. The findings of this study show that innate immunity cells, especially monocytes may contribute significantly to MS immunopathology.
ER  -

PETERKA, Marek, Martin VALIS, Ondrej SOUCEK, Jan KREJSEK, Lukas SOBISEK, Ilona SEJKOROVA, Blanka KLIMOVA, Pavel ŠTOURAČ, Zbysek PAVELEK a Michal NOVOTNY. Interferon beta-1a vs. glatiramer acetate: changes of innate immunity in a group of women with multiple sclerosis. \textit{EUROPEAN NEUROLOGY}. BASEL: KARGER, 2023, roč.~86, č.~5, s.~334-340, 14 s. ISSN~0014-3022. Dostupné z: https://dx.doi.org/10.1159/000532022.

Podrobný výpis o publikaci